The FDA has warned that common anti-epileptic drugs may increase the risk of suicide. The agency's review of clinical studies of 11 drugs -- including Pfizer's Lyrica and Johnson & Johnson's Topamax -- showed that patients using the drugs were twice as likely to have suicidal behavior as those who took a placebo. Pfizer said it hasn't found evidence of an increased risk of suicide-related events in Lyrica. Johnson & Johnson said the Topamax label already carries a discussion about suicide attempts.
Published in Brief: